Back Refine search Reset
Please choose a search criteria from below
Filters Clear all
Specialties
Treatments

100 results found in London, UK

Sort by:
Showing 11 - 20 of 100 results
General (Internal) Medicine
16 years of experience

Professor Peter Schmid is the Clinical Director of the St. Bartholomew Breast Cancer Centre, and Honorary Consultant Medical Oncologist and lead of the Cancer Immune Therapy group at Barts Hospital. He is also Professor of Cancer Medicine and Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute.

Professor Schmid studied medicine in Munich and Aberdeen. He was awarded scholarships by the German National Academic Foundation, the German Academic Exchange Service and the Hanns-Seidel-Foundation. Following this he completed specialist training in internal medicine, medical oncology and haematology in Berlin. Subsequently he undertook an MD in Clinical Chemistry at the Technical University Munich and a PhD in Medical Oncology at the Charité University in Berlin. In 2005, Professor Schmid moved to the UK and was appointed as Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. He was subsequently made Foundation Chair in Cancer Medicine at the University of Sussex.

He specialises in breast cancer, lung cancer and cancer immune therapy and is renowned internationally for this work in cancer immunotherapy. He was instrumental in the formation of the Cancer Immune Therapy group at Barts Hospital, which has become recognised globally as a leader in this field.

Professor Schmid has a particular research interest in triple negative breast cancer and endocrine resistance and has led more than 20 clinical studies and several translational research programmes in these areas. He also has an interest in personalised cancer medicine using novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. He currently leads an international group to establish blood-based circulating biomarkers.

He has authored or co-authored more than 150 publications and has published a book on the management of bone metastases. He is also regularly invited to speak at major international cancer conferences. Professor Schmid is a member of the breast cancer faculty of the European Society of Medical Oncology and has chaired several medical research committees. He was awarded the Breast Cancer Research Award 2012 by German Patient group Mammazone.

Professor Schmid has a strong interest in patient-doctor communication, for a number of years, he ran a programme training oncologists and oncology nurses in communication.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.


Diseases, Medical Tests and Treatments
  • Chemotherapy 
  • Immunotherapy 
  • Breast Cancer
  • Lung Cancer 
Read more
Oncology
30 years of experience
Clinical Oncology

Professor Andrew Tutt is a Consultant Clinical Oncologist specialising in breast cancer. He is based at Guy’s Hospital Breast Unit but also performs private work and is a Professor of Oncology at King’s College London School of Medicine.

He qualified in medicine in 1990 and went on to complete his postgraduate training at a number of hospitals around the UK. After completing his clinical oncology training at the Royal Marsden Hospital London, he was awarded a Doctoral Research Training Fellowship at The Institute of Cancer Research, London, where he gained his PhD in cancer biology.

Professor Tutt is actively involved in clinical research and has published a number of breast cancer research papers. His main areas of research include the ‘triple negative’ and BRCA1 and BRCA2 associated breast cancers. He has led a number of international trials of drug therapies and research programmes in these areas.

He is often asked to speak at major European and North American Cancer Medicine conferences. He is a member of the St Gallen International Breast Cancer Consensus Panel that develops guidelines for the treatment of breast cancer. He is also part of a UK team that trial new techniques in breast radiotherapy.


Diseases, Medical Tests and Treatments
  • Biological Therapy 
  • Chemotherapy 
  • Radiotherapy 
  • Breast Cancer 
Read more

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Read more
Oncology
30 years of experience
Clinical Oncology

Dr Beatrice Seddon is consultant on the Sarcoma Unit at University College Hospital, which together with the Bone Tumour Unit at the Royal National Orthopaedic Hospital, comprises the London Bone and Soft Tissue Tumour Service.

Dr Seddon trained in treating sarcomas at the Royal Marsden and Middlesex Hospitals in London, and now specialises exclusively in the treatment of soft tissue and bone sarcomas with chemotherapy and radiotherapy.

She completed her PhD (University of London) at the Institute of Cancer Research in imaging of tumour hypoxia, and currently has a strong interest in clinical trials in sarcoma, acting as principal and chief investigator for a number of national and international trials. She is actively involved in coordinating sarcoma research at a national level as a member of the NCRN Sarcoma Clinical Studies Group, and is also a member of the EORTC Soft Tissue and Bone Sarcoma Group. She regularly teaches and lectures on the management of sarcomas.

 

 


Diseases, Medical Tests and Treatments
  • Chemotherapy
  • Radiotherapy

 

  • Bone Cancer
  • Sarcoma

 

Read more
Oncology
14 years of experience
Medical Oncology

Dr Constantine Alifrangis is a Consultant Medical Oncologist in London. He specialises in the treatment of urological cancers including prostate, bladder, testicular and penile cancer.

He graduated from Guys’ Kings and St Thomas’ Medical school and was awarded the University Gold Medal for medicine. Following this, he completed his postgraduate medical training in oncology at Imperial College London. He undertook research into advanced prostate cancer at Hammersmith Hospital, and was awarded a Wellcome Trust fellowship to research the link between cancer genetics and the efficacy of novel therapies. He was awarded a PhD by the University of Cambridge in 2014 for this work. He was also awarded the Sylvia Lawler prize by the Oncology section of the Royal Society of Medicine.

In 2016, he was appointed Consultant Medical Oncologist at University College London Hospital and St Bartholomew’s. He is the Lead Oncologist for Testicular Cancer, treating patients with advanced prostate cancer and is part of a specialist team looking after patients with penile cancer.

He is actively involved in research into the genetic basis of cancer and drug resistance, including personalised approaches to cancer treatment. He is also the Lead Investigator for number of clinical studies looking at rarer and understudied cancers. He has presented his research at a number of international conferences and published research in various cancer journals including the Lancet, Journal of Clinical Oncology, and Clinical Cancer Research.


Diseases, Medical Tests and Treatments
  • Chemotherapy 
  • Bladder Cancer
  • Genito-urinary Cancer
  • Penile Cancer
  • Prostate Cancer
  • Testicular Cancer
Read more
Oncology
18 years of experience
Clinical Oncology

Dr. John Conibear completed his initial medical training at the University Hospital of Wales in 2001 and completed his post-graduate general medical training in The Barts and The London Training rotation in 2006. Before gaining his substantive post as a consultant clinical oncologist in St. Bartholomew’s Hospital in 2014, he completed a 2-year fellowship with the NCRI Radiotherapy Trials Quality Assurance Group in Mount Vernon Hospital. During his fellowship, he conducted research into techniques to improve clinician target outlining during radiotherapy planning and was subsequently awarded an MD(Res) from UCL in 2018.

Dr. Conibear is currently deputy medical director and deputy director of Barts Cancer Centre. Dr Conibear specialises in all the non-surgical treatments for both lung and breast cancers. He has expertise in chemotherapy, biological therapy, immunotherapy, radiotherapy and state of the art radiotherapy techniques including deep inspiration breath-hold (DIBH) for early breast cancer, Intensity Modulated Radiotherapy (IMRT), Image-Guided Radiotherapy (IGRT), 4D-CT and both Cyberknife and Gamma Knife (stereotactic radiotherapy). He is also currently the lead for chemotherapy and clinical director for thoracic oncology in St. Bartholomew’s Hospital in addition to his private practice.


Diseases, Medical Tests and Treatments
  • Chemotherapy
  • Deep Inspiration Breath Hold
  • Gamma Knife
  • Image-guided radiotherapy (IGRT)
  • Immunotherapy
  • Intensity modulated radiotherapy (IMRT)
  • Radiotherapy
  • Breast cancer
  • Lung cancer
Read more
Oncology
35 years of experience

Dr Katharine Pigott graduated from the University of London in 1995 having trained at The Middlesex Hospital. She specialised in Clinical Oncology training at The Westminster Hospital and Charing Cross Hospital. She also spent two years working as a research fellow at Mount Vernon Hospital and the Gray Laboratory running clinical trials in hyper fractionation and undertaking an MD in measuring late radiation damage. She took up a consultant post at The Royal Free in 1996 and worked there for twenty years specialising in the management and treatment of urological cancers and breast cancer.

During her time at The Royal Free, she was head of the Radiotherapy Department and Chair of The London Cancer Radiotherapy Expert Reference Group. Her clinical interests are research in breast and prostate cancer particularly in new radiotherapy technique and clinical trials. She was the radiotherapy lead for the TARGIT Academy at The Royal Free which taught intraoperative radiotherapy (IORT) to centres throughout the world and participated in the TARGIT trials.

She has published peer-review papers and co-edited books on the urological condition and intraoperative radiotherapy.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.


Diseases, Medical Tests and Treatments
  • Decision making for localised prostate cancer
  • Management of localised and metastatic prostate cancer
  • Management of breast cancer
  • External beam radiotherapy
  • Cyberknife
  • Rapid Arc/ Intensity-modulated radiotherapy
  • IORT intra-operative radiotherapy
  • Hormone treatment
  • Chemotherapy Radioisotope treatment
  • Decision making for localised prostate cancer
  • Management of localised and metastatic prostate cancer
  • Management of breast cancer
  • External beam radiotherapy
  • Cyberknife
  • Rapid Arc/ Intensity-modulated radiotherapy
  • IORT intra-operative radiotherapy
  • Hormone treatment
  • Chemotherapy Radioisotope treatment
Read more
Oncology
18 years of experience

Dr Timothy Robert Crook is a Consultant in Medical Oncology who works at The Princess Grace Hospital, The Harley Street Clinic, The Wellington Hospital and LOC.

He specialises in Bladder cancer, breast disease, chemotherapy, kidney cancer, oncology and skin cancer.


Diseases, Medical Tests and Treatments
  • Bladder cancer
  • Breast disease
  • Chemotherapy
  • Kidney cancer
  • Oncology
  • Skin cancer
  • Bladder cancer
  • Breast disease
  • Chemotherapy
  • Kidney cancer
  • Oncology
  • Skin cancer
Read more
Oncology
28 years of experience

Dr Cleator is an experienced breast and colorectal oncologist specializing in delivery of chemotherapy, targeted treatments and radiotherapy for early and advanced disease. Her NHS base is at Imperial Healthcare Trust (Charing Cross) and she consultants privately at LOC, Harley Street. She delivers treatment privately within the HCA and London Clinic facilities. 

Her initial medical training was gained at Oxford University. She has an academic background having undertaken a PhD based at the Institute of Cancer Research and Royal Marden Hospitals studying gene profiling as a means of personalizing chemotherapy delivery. She continues to be active in research and education. Particular interests include treatment of breast cancer in young women and pregnancy, neoadjuvant (pre surgical) treatment, personalization of treatment with use of gene assays and radiotherapy for early breast cancer. 

 

 

 

Read more
Oncology
29 years of experience
Medical Oncology

Professor Paul Ellis is a Consultant Medical Oncologist based in London, UK. He has a specialist interest in research into novel therapies in breast cancer management was heavily involved in chairing the UK Dept. of Health Advisory committee on the introduction of Herceptin into UK clinical practise, co-authoring the national guidelines of its use.

 

After attaining his Medical Degree from Otago University, New Zealand he then moved to London to complete his fellowship in Medical Oncology and postgraduate research degree at the Royal Marsden Hospital. It was here he submitted his MD thesis on the biological predictors of response to primary chemotherapy. 

 

Professor Paul Ellis continues to take an active leadership role within the UK and European Clinical Trials community. He was the principal investigator and co-chair in the trial management group for the UK National Adjuvant Chemotherapy (TACT) Trial and has been heavily involved on the Steering Committees of numerous other clinical trials of novel anti-cancer therapies including recently being Co-PI on the MARIANNE and KAMILLA trials. 

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Read more